PD-1 AND Tim-3 Expression on different subpopulations of monocytes in chronic often recurrent herpesvirus infection
- 作者: Rashchupkin I.M.1, Meledina I.V.2, Kotova M.A.2, Zheltova O.I.2
-
隶属关系:
- Research Institute of Fundamental and Clinical Immunology, Novosibirsk
- Research Institute of Fundamental and Clinical Immunology
- 期: 卷 14, 编号 3 (2024)
- 页面: 575-580
- 栏目: SHORT COMMUNICATIONS
- URL: https://journal-vniispk.ru/2220-7619/article/view/262083
- DOI: https://doi.org/10.15789/2220-7619-PAT-16807
- ID: 262083
如何引用文章
全文:
详细
More than half of the world’s population is infected with the herpes simplex virus. In most cases, infection is not accompanied by symptoms, but in some people the disease occurs as a chronic infection with frequent and severe relapses. One of the most likely reasons for this may be a dysregulation of the immune system. In recent years, the role of checkpoint molecules, in particular PD-1 and Tim-3, in the regulation of the immune response and the functions of immunocompetent cells has been actively studied. Activation of PD-1 and Tim-3 on T cells has previously been shown to suppress the immune response. PD-1 and Tim-3 are also expressed on other immune cells, in particular monocytes. However, the expression of these molecules on monocytes during chronic viral infections has not been previously studied. The study was aimed at assessing the level of PD-1 and Tim-3 expression on various populations of monocytes in patients with chronic often recurrent herpesvirus infection. Twenty-six patients were recruited into the study. All patients received antiviral and immunomodulatory therapy in the immunological department. The number of classical, intermediate, and non-classical monocytes and the expression of PD-1 and Tim-3 on monocytes, were assessed by flow cytometry before and after the therapy. Monocytes were isolated from peripheral blood, and subpopulations were divided according to the level of expression of CD14 and CD16. In patients with herpes, a reduced number of monocytes was observed in comparison with healthy donors. The relative number of PD-1-positive monocytes, the mean fluorescence intensity of PD-1 and Tim-3, and the number of double-positive cells were reduced in herpes patients in all three monocyte subpopulations examined. Three months after therapy, the response to the therapy was assessed; patients who did not have a single recurrence of herpes within 3 months were considered to respond. Responding patients had a lower initial content of double-positive cells among intermediate and non-classical monocytes. The decrease in the level of PD-1 and Tim-3 positive monocytes during herpesvirus infection revealed in the present study may indicate the involvement of monocytes deficient in the expression of checkpoint molecules in the pathogenesis of the disease.
作者简介
Ivan Rashchupkin
Research Institute of Fundamental and Clinical Immunology, Novosibirsk
编辑信件的主要联系方式.
Email: iwwwanbets@mail.ru
Research Laboratory Assistant, Laboratory of Cellular Immunotherapy
俄罗斯联邦, 630099, Novosibirsk, Yadrintsevskaya str., 14I. Meledina
Research Institute of Fundamental and Clinical Immunology
Email: iwwwanbets@mail.ru
PhD (Medicine), Allergist-Immunologist, Head of the Immunology Department, Clinic of Immunopathology
俄罗斯联邦, 630099, Novosibirsk, Yadrintsevskaya str., 14M. Kotova
Research Institute of Fundamental and Clinical Immunology
Email: iwwwanbets@mail.ru
Allergist-Immunologist, Immunology Department, Clinic of Immunopathology
俄罗斯联邦, 630099, Novosibirsk, Yadrintsevskaya str., 14O. Zheltova
Research Institute of Fundamental and Clinical Immunology
Email: iwwwanbets@mail.ru
PhD (Medicine), Allergist-Immunologist, Immunology Department, Clinic of Immunopathology
俄罗斯联邦, 630099, Novosibirsk, Yadrintsevskaya str., 14参考
- Antonsen K.W., Hviid C.V.B., Hagensen M.K., Sorensen B.S., Moller H.J. Soluble PD-1 (sPD-1) is expressed in human macrophages. Cell. Immunol., 2021, vol. 369: 10⁴435. doi: 10.1016/j.cellimm.2021.10⁴435
- Bellner L., Thoren F., Nygren E., Liljeqvist J.-A., Karlsson A., Eriksson K. A proinflammatory peptide from herpes simplex virus type 2 glycoprotein G affects neutrophil, monocyte, and NK cell functions. J. Immunol., 2005, vol. 174, no. 4, pp. 2235–2241. doi: 10.4049/jimmunol.174.4.2235
- Das M., Zhu C., Kuchroo V.K. Tim-3 and its role in regulating anti-tumor immunity. Immunol. Rev., 2017, vol. 276, no. 1, pp. 97–111. doi: 10.1111/imr.12520
- Ghosh C., Luong G., Sun Y. A snapshot of the PD-1/PD-L1 pathway. J. Cancer, 2021, vol. 12, no. 9, pp. 2735–2746. doi: 10.7150/jca.57334
- Guglietta S., Krieg C. Phenotypic and functional heterogeneity of monocytes in health and cancer in the era of high dimensional technologies. Blood Rev., 2023, vol. 58: 101012. doi: 10.1016/j.blre.2022.101012
- Guignant C., Lepape A., Huang X., Kherouf H., Denis L., Poitevin F., Malcus C., Cheron A., Allaouchiche B., Gueyffier F., Ayala A., Monneret G., Venet F. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Critical Care, 2011, vol. 15, no. 2: R99. doi: 10.1186/cc10112
- Ozanska A., Szumczak D., Rybka J. Pattern of human monocyte subpopulations in health and disease. Scand. J. Immunol., 2020, vol. 91, no. 1: e12883. doi: 10.1111/sji.12883
- Skrzeczynska-Moncznik J., Bzowska M., Loseke S., Grage-Griebenow E., Zembala M., Pryjma J. Peripheral blood CD14high CD16⁺ monocytes are main producers of IL-10. Scand. J. Immunol., 2011, vol. 67, no. 2, pp. 152–159. doi: 10.1111/j.1365-3083.2007.02051.x
- Van Wagoner N., Qushair F., Johnston C. Genital herpes infection: progress and problems. Infect. Dis. Clin. North Am., 2023, vol. 37, no. 2, pp. 351–367. doi: 10.1016/j.idc.2023.02.011
- Xia Q., Wei L., Zhang Y., Sheng J., Wu W., Zhang Y. Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients. Mediators Inflamm., 2018, vol. 2018: 1632902. doi: 10.1155/2018/1632902
- Zhu S., Viejo-Borbolla A. Pathogenesis and virulence of herpes simplex virus. Virulence, 2021, vol. 12, no. 1, pp. 2670–2702. doi: 10.10⁸0/21505594.2021.1982373
补充文件
